Axelopran is under clinical development by Glycyx MOR and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axelopran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Axelopran overview

Axelopran is under development for the treatment of refractory or metastatic recurrent head and neck cancer squamous cell carcinoma, non-small cell lung cancer, solid tumor, metastatic melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and advanced pancreatic cancer. The drug candidate is administered orally. It is a small molecule. TD-1211 acts by selectively targeting mu opioid receptor.

It was under development for the treatment of opioid-induced constipation (OIC). 

Glycyx MOR overview

Glycyx MOR a pharmaceutical manufacturing company which focuses to normalize immune function and inflammation in cancer and other related serious diseases. Glycyx MOR is headquartered in San Francisco, California, the US.

For a complete picture of Axelopran’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.